

**Testimony of Maine Public Health Association in Support of:
LD 132: An Act to Require Health Insurance Carriers to Provide Coverage for Blood Testing for
Perfluoroalkyl and Polyfluoroalkyl Substances**

Joint Standing Committee on Health Coverage, Insurance and Financial Services
Room 220, Cross State Office Building
Tuesday, March 28, 2023

Good afternoon, Senator Bailey, Representative Perry, and distinguished members of the Joint Standing Committee on Health Coverage, Insurance and Financial Services. My name is Denise Tepler. I am a resident of Topsham and board member of Maine Public Health Association. MPHA is in support of LD 132: "An Act to Require Health Insurance Carriers to Provide Coverage for Blood Testing for Perfluoroalkyl and Polyfluoroalkyl Substances."

MPHA is the state's oldest, largest, and most diverse association for public health professionals. We represent more than 700 individual members and 60 organizations across the state. The mission of MPHA is to improve and sustain the health and well-being of all people in Maine through health promotion, disease prevention, and the advancement of health equity. As a statewide nonprofit association, we advocate, act, and advise on critical public health challenges, aiming to improve the policies, systems, and environments that underlie health inequities – but which also have potential to improve health outcomes for all people in Maine. We are not tied to a national agenda, which means we are responsive to the needs of Maine's communities, and we take that responsibility seriously.

The proposed bill would require all private health insurance carriers providing coverage in the state of Maine to cover the costs of blood testing for perfluoroalkyl and polyfluoroalkyl substances (PFAS) for their enrollees, starting January 1, 2024.

According to the U.S. Environmental Protection Agency, PFAS are found in air, soil, surface water, and groundwater (including drinking water); food and food packaging; commercial household products; and some living organisms (where PFAS have accumulated over time). PFAS remain in the body for long periods of time (anywhere from months to years) after they have entered it. PFAS contamination has been identified in well-water sources and farm fields across the state of Maine, putting those who rely on those resources at risk of hazardous chemical exposures.

There is evidence from human and animal studies that PFAS exposure may reduce antibody responses to vaccines' and infectious disease resistance, alter metabolism and fertility, reduce fetal growth and increase the risk of being overweight or obese. PFAS exposure has been associated with several chronic health problems, including increased cholesterol levels, liver dysfunction, and increased risk of testicular and kidney cancers. A recent review of the research literature explored the relationship between PFAS exposure and children's health. Six associations with health were identified: early puberty onset, immunity/infection/asthma, thyroid and renal function, cardio-metabolic measures, and neurodevelopmental/attention.

The National Academy of Sciences, Engineering, and Medicine recommends PFAS blood serum tests for people who are likely to have a history of elevated exposure to PFAS, including communities with documented exposure, people living near farms where sludge may have been spread, people with an occupational exposure

risk, including firefighters, and people living near landfills, incinerators, airports, and military bases.

Treatment for PFAS exposure starts with assessing patients' level of exposure, and if patients have elevated serum levels, then continued health monitoring. There is no approved procedure to remove PFAS chemicals from an exposed person's body. However, the assessment of personal exposure can help impacted patients understand their health risks and take steps to prevent, or mitigate, future adverse health effects, including dyslipidemia, thyroid dysfunction, and testicular cancer.

Currently, many private Maine insurers leave patients to cover the full cost of the serum test unless their deductible has been reached. The approximately \$600 per person cost of the serum test is currently preventing PFAS-impacted Mainers from assessing their exposure and monitoring their risk for other negative health impacts.

It is clear PFAS exposure poses a risk to public health. As such, we support efforts to improve our understanding of our own exposure and ability to minimize potential health risks. We support the intention of this bill and believe it is protective of public health. We respectfully request you vote LD 132 "Ought to Pass." Thank you.

122 State Street, Augusta, ME 04330 • 207-808-0487 •
mainepublichealth.org